MS and Demyelinating Disorders

The trial will determine whether autologous hematopoietic stem cell transplantation is a more appropriate treatment option for patients with severe forms of relapsing MS compared to currently available biologic drugs.

More aggressive strategies in the treatment of multiple sclerosis have created an opportunity for physicians to refine the way they address a first demyelinating event, and perhaps change the course of disease.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

The director of the Jefferson Headache Center at Thomas Jefferson University detailed the most notable achievements from 2019, and what to expect in the coming year.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Given the data, Adamas has stated that it will forgo its originally planned second phase 3 placebo-controlled study, instead continuing its open-label extension study and engaging the FDA to discuss ADS-5102’s regulatory pathway.

The study reported that those with MS who breastfed experienced 43% lower rates of postpartum relapse compared to those who did not.

Although there are gaps in knowledge, investigators see potential in telemedicine for other neurologic disorders beyond stroke.

The FDA granted approvals to HEC Pharm Co. Limited, Biocon Limited, and Sun Pharmaceutical Industries Limited, for their generic formulations of Novartis’ product, branded as Gilenya, for the treatment of relapsing forms of multiple sclerosis.

Both the busy clinician and the overwhelmed patient benefit from a pointed approach to disease management.

Diagnoses have increased with disease awareness, highlighting a great need for markers to help influence treatment decisions.

A growing emphasis on access to care and ease of use drives a digital revolution in the treatment of mental comorbidities in multiple sclerosis.

The assistant professor of clinical neurology at Keck School of Medicine University of Southern California in Los Angeles sat down with NeurologyLive for a Q&A discussing using steroids as treatment for multiple sclerosis.

The benefits of a multidisciplinary hub for disease management can mitigate the costs.

Although there are no cures for MS at present, the treatment landscape has changed significantly, with over a dozen approved disease-modifying therapies (DMTs) representing multiple classes of agents with different mechanisms of action.

Results from the phase 3 EVOLVE-MS-2 study demonstrate superior tolerability for now-approved diroximel fumarate compared to dimethyl fumarate.

The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.

The director of Centers for Neuropsychology and Neuroscience Research and Traumatic Brain Injury Research at Kessler Foundation spoke to the use of strategy training and how it mirrors real-life situations for patients with MS and TBI.

The neurologist at Cleveland Clinic outlines the need to better understand the biology of progressive MS in order to make substantial headway in its treatment.

Neurology News Network for the week ending October 28, 2019.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

The neurologist at Cleveland Clinic discusses the clinical considerations included in the decision to stop treatment of MS in patients with progressive disease.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

The staff neurologist at Cleveland Clinic addressed several questions regarding choosing an optimal therapy for patients with MS.

The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.